Journal article icon

Journal article

Benralizumab for the prevention of COPD exacerbations

Abstract:

BACKGROUND

The efficacy and safety of benralizumab, an interleukin-5 receptor alpha–directed cytolytic monoclonal antibody, for the prevention of exacerbations in patients with moderate to very severe chronic obstructive pulmonary disease (COPD) are not known.

METHODS

In the GALATHEA and TERRANOVA trials, we enrolled patients with COPD (at a ratio of approximately 2:1 on the basis of eosinophil count [≥220 per cubic millimeter vs. ≺220 per cubic milli...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed

Actions


Access Document


Files:
Publisher copy:
10.1056/nejmoa1905248

Authors


More by this author
Role:
Author
ORCID:
0000-0002-7266-8371
Expand authors...
AstraZeneca More from this funder
Kyowa Hakko More from this funder
Publisher:
Massachusetts Medical Society Publisher's website
Journal:
New England Journal of Medicine Journal website
Volume:
381
Issue:
11
Pages:
1023-1034
Publication date:
2019-05-20
Acceptance date:
2019-05-16
DOI:
ISSN:
1533-4406 and 0028-4793
Pmid:
31112385
Source identifiers:
1007327
Language:
English
Pubs id:
pubs:1007327
UUID:
uuid:3d078cbe-8ab8-4c1a-857a-12f9887d569a
Local pid:
pubs:1007327
Deposit date:
2019-06-10

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP